课题基金 / 基金详情

Class II MHC Protein and Tetramer Core

Class II MHC Protein and Tetramer Core
II 类 MHC 蛋白和四聚体核心
批准号:
7698599
负责人:
Lawrence J. Stern
金额:
$18.09万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-15 至 2009-03-31

项目摘要

项目成果

Lawrence J. Stern的其他基金

相似基金

相关文献

中文摘要
翻译
II类MHC蛋白和四聚体核心将支持研究项目1-3和TDC
英文摘要
The Class II MHC Protein and Tetramer Core will support Research Projects 1-3 and the TDC by providing Class II MHC proteins and tetramers carrying Category A-C agent peptides. The specific aims of the proposed core facility are to generate HLA-DRl-peptide tetramers for use in quantifying and characterizing CD4+ T cells responding to category A-C viruses, to generate purified HLA-DRl-peptide complexes for use in development of microassays to detect CD4+ T cells, and to investigate the production of human class II MHC proteins other than HLA-DR1 for use as purified MHC-peptide complexes and tetramers. These are specialized reagents not available commercially. Production in a core facility will provide economies of scale, standardized production, and reagent testing, and will facilitate production of additional alleles. The ready availability of HLA-DR-peptide proteins and tetramers should greatly enhance the ability of the Research Projects to enumerate, isolate, and characterize virus-specific CD4+ T cell responses, and the ability of the TDC to develop and validate new technology for identification of T cell epitopes and characterization of antigen-specific T cell functional responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ER-aminopeptidases: Conformational regulation and antigen presentation function
ER-aminopeptidases: Conformational regulation and antigen presentation function
ER-aminopeptidases: Conformational regulation and antigen presentation function
HLA-DO / H2-O: modulation of MHC-II peptide diversity and Treg population control
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究